Business Context and Reporting Period
This Form 8-K filing by Aadi Bioscience, Inc. (AADI) covers events occurring on February 28, 2025, and March 4, 2025. The report details the results of a Special Meeting of Stockholders held on February 28, 2025, and the subsequent consummation of a Private Placement (PIPE Financing) on March 4, 2025. The company is a Delaware corporation trading on The Nasdaq Stock Market.
Key Financial Metrics and Transactions
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, or operating margins for a specific reporting period. Instead, it focuses on capital structure changes and transaction terms:
- PIPE Financing: Issuance of 21,592,000 shares of common stock at $2.40 per share and pre-funded warrants for up to 20,076,500 shares at $2.3999 per warrant.
- Divestiture: Approval of the sale of 100% of Aadi Subsidiary, Inc. (FYARRO Business) to KAKEN INVESTMENTS INC.
- Equity Plan: Increase in shares available for grant under the 2021 Equity Incentive Plan from 2,000,284 to 8,300,284 shares.
- Liquidity: The filing does not state current cash balances or debt levels, only the terms of the new capital raise.
Material Changes and Voting Results
At the Special Meeting, 20,105,684 shares (approximately 81.41% of voting power) were present. All five proposals were approved by stockholders. The voting results were as follows:
| Proposal | For Votes | Against Votes | Abstentions |
|---|---|---|---|
| 1. Divestiture (Sale of FYARRO Business) | 16,606,498 | 3,495,206 | 3,980 |
| 2. PIPE Financing | 12,898,905 | 7,202,353 | 4,426 |
| 3. Equity Plan Increase | 11,863,025 | 8,234,637 | 8,022 |
| 4. Executive Compensation (Golden Parachutes) | 15,490,810 | 4,598,457 | 16,417 |
| 5. Adjournment Authority | 15,121,060 | 4,948,986 | 35,638 |
Outlook, Management Commentary, and Risks
Registration Rights: The Company entered into a Registration Rights Agreement with PIPE purchasers. A resale registration statement must be filed within 30 days of closing or 5 business days after filing audited financial statements for the year ended December 31, 2024, whichever is later. The Company aims to have this statement declared effective within 60 days (or 90 days if reviewed by the SEC).
Equity Plan Amendment: The 2021 Plan was amended to increase the annual automatic share reserve increase from 4% to 5% of outstanding shares.
Risks and Contingencies: The filing notes that the Divestiture Proposal may be deemed a sale of substantially all assets under Delaware General Corporation Law. The Registration Rights Agreement includes indemnification provisions for participating holders against losses related to the registration statement.
Key Facts for Investor Verification
- Verify the final closing date and total capital raised from the PIPE Financing (21.6M shares + 20.1M warrants) as announced in the March 4, 2025 press release.
- Confirm the timeline for the resale registration statement effectiveness, as this impacts the liquidity of the new shares.
- Review the definitive Stock Purchase Agreement to understand the specific terms of the FYARRO Business divestiture to KAKEN INVESTMENTS INC.
- Assess the impact of the increased equity plan reserve (now 8.3M shares) on future dilution.
- Check the audited financial statements for the year ended December 31, 2024, once filed, to understand the company's liquidity position post-divestiture.